188.93

0.27% 0.51

After Hours: 188.94 0.010 +0.01%

Astrazeneca Plc (AZN)

Overview News Price History Option Chain Why AZN Down? Discussions Forecast Stock Split Dividend History

Astrazeneca Plc stock is traded at $188.93, with a volume of 1.47M. It is up +0.27% in the last 24 hours and down -9.44% over the past month. A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.

Previous Close:

$188.42

Open:

$186.73

24h Volume:

1.47M

Relative Volume:

0.31

Market Cap:

$293.00B

Revenue:

$58.80B

Net Income/Loss:

$10.24B

P/E Ratio:

57.62

EPS:

3.2788

Net Cash Flow:

$8.98B

1W Performance:

-1.85%

1M Performance:

-9.44%

6M Performance:

+147.68%

1Y Performance:

+147.55%

1-Day Range:

$186.33

$189.79

1-Week Range:

$186.33

$193.96

52-Week Range:

$61.24

$212.71

Astrazeneca Plc Stock (AZN) Company Profile

Name

Astrazeneca Plc

Sector

Healthcare (1114)

Industry

Drug Manufacturers - General (20)

Phone

Address

Employee

96,100

Twitter

@AstraZeneca

Next Earnings Date

2026-02-10

Latest SEC Filings

AZN's Discussions on Twitter

Compare AZN vs LLY, JNJ, ABBV, NVS

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AZN Astrazeneca Plc	188.93	292.21B	58.80B	10.24B	8.98B	3.2788
LLY Lilly Eli Co	917.50	819.81B	65.18B	20.64B	5.96B	22.59
JNJ Johnson Johnson	237.60	571.52B	94.19B	26.80B	19.70B	11.05
ABBV Abbvie Inc	206.23	368.38B	61.16B	4.19B	17.82B	2.3614
NVS Novartis Ag Adr	148.19	285.86B	54.72B	14.02B	15.32B	7.1855

Astrazeneca Plc Stock (AZN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-27-26	Initiated	Citigroup	Buy
Oct-27-25	Resumed	Jefferies	Buy
Oct-16-25	Downgrade	Deutsche Bank	Hold → Sell
Apr-15-25	Initiated	Exane BNP Paribas	Outperform
Feb-13-25	Upgrade	UBS	Neutral → Buy
Feb-12-25	Initiated	Morgan Stanley	Overweight
Nov-20-24	Upgrade	UBS	Sell → Neutral
Nov-06-24	Upgrade	Deutsche Bank	Sell → Hold
Sep-13-24	Downgrade	Deutsche Bank	Hold → Sell
May-30-24	Initiated	Goldman	Buy
Apr-16-24	Upgrade	Deutsche Bank	Sell → Hold
Feb-08-24	Downgrade	Deutsche Bank	Hold → Sell
Jan-23-24	Initiated	Morgan Stanley	Overweight
Jan-16-24	Resumed	UBS	Sell
Jan-03-24	Downgrade	Jefferies	Buy → Hold
Dec-18-23	Initiated	HSBC Securities	Buy
Sep-25-23	Upgrade	Jefferies	Hold → Buy
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-12-23	Upgrade	UBS	Neutral → Buy
Jul-05-23	Downgrade	Deutsche Bank	Buy → Hold
Apr-11-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-05-23	Initiated	BMO Capital Markets	Outperform
Sep-15-22	Downgrade	Credit Suisse	Outperform → Neutral
Sep-07-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-29-22	Upgrade	Argus	Hold → Buy
Jun-14-22	Downgrade	UBS	Buy → Neutral
Feb-11-22	Upgrade	DZ Bank	Sell → Hold
Dec-07-21	Downgrade	Jefferies	Buy → Hold
Aug-12-21	Resumed	JP Morgan	Overweight
Apr-12-21	Downgrade	Argus	Buy → Hold
Mar-16-21	Upgrade	Jefferies	Hold → Buy
Feb-25-21	Upgrade	UBS	Neutral → Buy
Jan-15-21	Initiated	Deutsche Bank	Buy
Dec-07-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-30-20	Upgrade	UBS	Sell → Neutral
Nov-11-20	Upgrade	HSBC Securities	Reduce → Hold
Sep-29-20	Initiated	Berenberg	Buy
Nov-22-19	Initiated	SVB Leerink	Outperform
Oct-25-19	Upgrade	Liberum	Hold → Buy
Apr-02-19	Downgrade	UBS	Neutral → Sell
Feb-05-19	Initiated	Exane BNP Paribas	Outperform
Jan-25-19	Upgrade	Shore Capital	Hold → Buy
Dec-11-18	Resumed	Jefferies	Hold
Oct-09-18	Initiated	Guggenheim	Buy
Aug-16-18	Downgrade	Jefferies	Buy → Hold
Mar-19-18	Upgrade	Jefferies	Hold → Buy
Feb-06-18	Reiterated	Leerink Partners	Mkt Perform
Feb-05-18	Reiterated	Bernstein	Outperform
Jan-18-18	Reiterated	Leerink Partners	Mkt Perform
Dec-29-17	Upgrade	JP Morgan	Neutral → Overweight
Oct-16-17	Upgrade	Credit Suisse	Neutral → Outperform
Sep-25-17	Upgrade	Exane BNP Paribas	Neutral → Outperform
Sep-22-17	Upgrade	Bernstein	Mkt Perform → Outperform

View All

Astrazeneca Plc Stock (AZN) Latest News

01:04 AM

AstraZeneca Expands Real-World Push With New China Kidney Registry - TipRanks

01:04 AM

12:35 PM

AstraZeneca’s REVIVE Trial Targets Relapse After Osimertinib, Extending the Lung Cancer Playbook - TipRanks

12:35 PM

09:26 AM

AstraZeneca to boost cell therapy capabilities with new China investment - BioPharma Dive

09:26 AM

07:40 AM

Jacobio Pharma Poised To Turn A Profit From Precision Cancer Drugs - Benzinga

07:40 AM

07:36 AM

Wilmington Savings Fund Society FSB Cuts Stock Position in Astrazeneca Plc $AZN - MarketBeat

07:36 AM

06:36 AM

Hudson Bay Capital Management LP Acquires 128,256 Shares of Astrazeneca Plc $AZN - MarketBeat

06:36 AM

12:52 PM

AstraZeneca to build cell therapy base, innovation centre in Shanghai - marketscreener.com

12:52 PM

Mar 18, 2026

AstraZeneca Makes Soliris Available In Malaysia For Rare Disease Treatment - bernama

Mar 18, 2026

Cowen Maintains AZN AstraZeneca PLC at Buy on March 18, 2026 - Meyka

Mar 18, 2026

AstraZeneca: The $6 Billion Imfinzi Story Is Expanding Beyond Lung Cancer - Smartkarma

Mar 18, 2026

Challenges for AstraZeneca (AZN) Amid Drug Pricing Claims - GuruFocus

Mar 18, 2026

Why AstraZeneca PLC (AZN) is one of the best immunotherapy stocks to buy according to hedge funds - MSN

Mar 18, 2026